DFTX Definium Therapeutics, Inc.
Company Analysis
Latest News
🟢 Definium Therapeutics, Inc. is trading 4.37% up
DFTX is trading at $44.67, up 4.37%.
🔴 Definium Therapeutics is trading 4.1% down today on profit-taking after recent Phase 3 trial-driven rally
Definium Therapeutics is trading 4.1% down at $43.80 as shares pull back following a sharp rally driven by positive Phase 3 Emerge trial results for DT120 ODT...
🟢 Definium Therapeutics, Inc. is trading 7.31% up in pre-market
DFTX is trading at $49.00, up 7.31% in pre-market.
🟢 Definium Therapeutics is trading 4.4% up today on technical rebound after sector weakness
Definium Therapeutics is trading 4.4% up at $45.55 as shares rebound from Monday’s technical pullback and broader biotech sector weakness. • The stock is...
🔴 Definium Therapeutics is trading 4.6% down today on technical pullback and broader biotech weakness
Definium Therapeutics is trading 4.6% down at $44.92 as the stock undergoes a technical pullback following its recent rally and broader biotech sector...
🔴 Definium Therapeutics is trading 4.6% down today in a post-rally consolidation
Definium Therapeutics is trading at $46.24 (-4.57%) as the stock undergoes a technical pullback following a sharp +6.91% gain on July 9. • The recent price...
🟢 Definium Therapeutics is trading 4.1% up today following positive Phase 3 trial results and a $700M capital raise
Definium Therapeutics is trading at $47.17 (+4.1%), extending its recent strength after reporting positive clinical data and completing a significant equity...
Definium Therapeutics defeats LSD trade-secret lawsuit, clearing path for drug development
A federal judge in Delaware dismissed a trade-secret lawsuit against psychedelic therapy developer Definium Therapeutics. Clinical-trial provider Signant...
🔴 DFTX extends move to 5.0% down
DFTX is trading at $44.68, down 5.0% versus the comparison close of $47.04 during regular trading. This is a price-movement alert; no separate company-specific...
🔴 Definium Therapeutics, Inc. is trading 4.29% down
DFTX is trading at $45.02, down 4.29%.
🟢 DFTX extends move to 5.2% up
DFTX is trading at $48.98, up 5.2% versus the comparison close of $46.55 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 DFTX is trading 4.2% up today on Oppenheimer upgrade and DT120 trial progress
DFTX is trading 4.2% up at $48.52 following a recent Oppenheimer upgrade to a $60 price target and positive DT120 clinical trial progress. • The move extends...
🔴 DFTX is trading 4.1% down today after closing an upsized $805M equity offering
DFTX is trading at $42.95 (4.1% down) as investors digest the impact of a large, upsized equity raise following its recent clinical rally. • The company...
Definium Therapeutics Secures $758 Million, Advancing Late-Stage Psychiatric Pipeline
Definium Therapeutics, Inc. closed its underwritten public offering of 20,588,236 common shares. The shares were priced at $34.00 per share. The offering was...
🟢 DFTX makes sharp 10.7% jump
DFTX is trading at $46.62, up 10.7% versus the comparison close of $42.13 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 DFTX is trading 6.5% up today after pricing $805M equity offering to fund CNS pipeline
DFTX is trading 6.5% up at $44.88 as investors react to its upsized $805 million equity raise. • The company priced an underwritten public offering of common...
Definium Therapeutics Announces ~$805M Public Offering of Common Stock
Definium Therapeutics, Inc. has entered into an underwriting agreement for a public offering of its common shares, expecting to raise approximately $758...
🟢 DFTX is trading 17% up today on Phase 3 trial success and $700M equity offering
DFTX is trading 17% up at $42.19 as investors react to positive Phase 3 results for its depression drug candidate and a significant capital raise. • The stock...
🟢 DFTX is trading 6.4% up today on Phase 3 Emerge data and analyst upgrades
DFTX is trading at $38.49 (+6.38%) in pre-market following a sharp rerating driven by positive Phase 3 Emerge data for DT120 ODT in major depressive...
🟢 DFTX is trading 5.2% up today as investors cheer Phase 3 data and analyst upgrades
DFTX is trading 5.2% up at $38.59 as shares rebound from an equity offering pullback, with investors refocusing on positive Phase 3 clinical data for its...